Presentation is loading. Please wait.

Presentation is loading. Please wait.

Adverse Event (AE) Coding Data mining and cleaning Medical literature screening and report writing Cleaning juggled Drug- AE data and converting to machine.

Published byAsher French Modified over 7 years ago

Similar presentations

Presentation on theme: "Adverse Event (AE) Coding Data mining and cleaning Medical literature screening and report writing Cleaning juggled Drug- AE data and converting to machine."— Presentation transcript:

1

2 Adverse Event (AE) Coding Data mining and cleaning Medical literature screening and report writing Cleaning juggled Drug- AE data and converting to machine readable excel format Consolidated report comparing clinical trials of a diabetic drug MedDRA coding, Serious AE coding

3 Detailed annotated analysis and classification of Drug- AE- Disease relations Medical literature screening and analysis Risk/Benefit profile of a drug Comparison of safety and efficacy profile of newly approved drugs with existing drugs

Download ppt "Adverse Event (AE) Coding Data mining and cleaning Medical literature screening and report writing Cleaning juggled Drug- AE data and converting to machine."

Similar presentations

The Information Professionals Role in Product Safety Jack Leitmeyer Director, Adverse Experience Information Management Worldwide Product Safety Merck.

The Information Professionals Role in Product Safety Jack Leitmeyer Director, Adverse Experience Information Management Worldwide Product Safety Merck.
Pharmacovigilance by Dr. Notghi Contract Research.

Pharmacovigilance by Dr. Notghi Contract Research.
Common Terminology Criteria for Adverse Events (CTCAE) v.4: Updating a Cancer Research Standard Ann Setser 1, Ranjana Srivastava 2, Lawrence Wright 1,

Common Terminology Criteria for Adverse Events (CTCAE) v.4: Updating a Cancer Research Standard Ann Setser 1, Ranjana Srivastava 2, Lawrence Wright 1,
5S CLÍNICA MÉDICA (MH) 306 A. 5S CLÍNICA MÉDICA (MH) 306 B.

5S CLÍNICA MÉDICA (MH) 306 A. 5S CLÍNICA MÉDICA (MH) 306 B.
Montalescot G, et al. Lancet 2009;373:723-31. Trial profile Montalescot G, et al. Lancet 2009;373:723-31.

Montalescot G, et al. Lancet 2009;373: Trial profile Montalescot G, et al. Lancet 2009;373:
FDA Perspective Sally Loewke, M.D. Acting Division Director

FDA Perspective Sally Loewke, M.D. Acting Division Director
Code 2 Layers. Step 1 Using 2 Layers Step 2: There are 2 layers Using 2 Layers.

Code 2 Layers. Step 1 Using 2 Layers Step 2: There are 2 layers Using 2 Layers.
Knowledge Update Clinical documentation: from preclinical studies to drug registration Split, 12 September 2008.

Knowledge Update Clinical documentation: from preclinical studies to drug registration Split, 12 September 2008.
Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.

Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.
Clinical Data Management is involved in all aspects of processing the clinical data, working with a range of computer applications, database systems.

Clinical Data Management is involved in all aspects of processing the clinical data, working with a range of computer applications, database systems.
JumpStart the Regulatory Review: Applying the Right Tools at the Right Time to the Right Audience Lilliam Rosario, Ph.D. Director Office of Computational.

JumpStart the Regulatory Review: Applying the Right Tools at the Right Time to the Right Audience Lilliam Rosario, Ph.D. Director Office of Computational.
Safety data collected during clinical trials is incorporated into the product’s approved label. Regulatory reviewers monitor products’ safety profiles.

Safety data collected during clinical trials is incorporated into the product’s approved label. Regulatory reviewers monitor products’ safety profiles.
Pharmacovigilance obligations of the Pharmaceutical companies in India

Pharmacovigilance obligations of the Pharmaceutical companies in India
Examples of ADE Surveillance Systems MedDRA ® Processing of Adverse Event Reports in ADE Surveillance Systems Amarilys Vega, M.D, M.P.H., Sonja Brajovic,

Examples of ADE Surveillance Systems MedDRA ® Processing of Adverse Event Reports in ADE Surveillance Systems Amarilys Vega, M.D, M.P.H., Sonja Brajovic,
FDA Focus On Consumer Protection

FDA Focus On Consumer Protection
ACCREDITED CONSULTANTS PVT LTD. (ACPL) WELCOMES YOU Your PHARMACOVIGILANCE PARTNER.

ACCREDITED CONSULTANTS PVT LTD. (ACPL) WELCOMES YOU Your PHARMACOVIGILANCE PARTNER.
The New Drug Development Process (www. fda. gov/cder/handbook/develop

The New Drug Development Process (www. fda. gov/cder/handbook/develop
OFEV ® (nintedanib) safety Safety data INPULSIS ® -1 & -2 These slides are provided by Boehringer Ingelheim for medical to medical education only. Last.

OFEV ® (nintedanib) safety Safety data INPULSIS ® -1 & -2 These slides are provided by Boehringer Ingelheim for medical to medical education only. Last.
Bernhard Breil, Benjamin Trinczek, Martin Dugas Dr. Bernhard Breil Portal of Medical Data Models – An open repository of Forms MedInfo 2013, Copenhagen.

Bernhard Breil, Benjamin Trinczek, Martin Dugas Dr. Bernhard Breil Portal of Medical Data Models – An open repository of Forms MedInfo 2013, Copenhagen.
FDA1 Overview of Postmarketing Safety Surveillance in FDA (For Drugs and Biologics) Min Chen, M.S., R.Ph. Min Chen, M.S., R.Ph. Associate Director Division.

FDA1 Overview of Postmarketing Safety Surveillance in FDA (For Drugs and Biologics) Min Chen, M.S., R.Ph. Min Chen, M.S., R.Ph. Associate Director Division.

Similar presentations

Ads by Google